Search

everythinglearnresearchcommunity

for

Search:↓

Breast cancer hormone therapy can cause hair loss, which can be treated with daily applications of specific topical solutions like minoxidil and hydrocortisone butyrate.

Aromatase inhibitor therapy for breast cancer increases the risk of hair loss and thinning.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

Targeting vitamin D and androgen receptors may effectively treat triple-negative breast cancer, especially with chemotherapy.

Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.

Local hormonal treatment for vulvovaginal atrophy is likely safe for women with estrogen receptor-positive breast cancer on aromatase inhibitors.

Some breast cancer patients on hormonal therapy may develop male or female pattern hair loss, which can sometimes be improved with topical treatments.

A breast cancer patient had lasting hair loss after chemotherapy, which improved with minoxidil treatment.

Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.

Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.

A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.

Treatment strategies for breast cancer affect blood health, causing issues like anemia and require nutritional counseling.

Docetaxel and paclitaxel for breast cancer can cause permanent, severe hair loss.

CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.

Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.

EGFR inhibitors in breast cancer treatment can cause serious skin issues affecting patient quality of life.

Low-dose oral minoxidil combined with topical minoxidil improves hair growth in breast cancer patients with therapy-induced hair loss.

Resistance exercise improves body image in breast cancer survivors.

Docetaxel chemotherapy causes more long-term hair loss and dissatisfaction than paclitaxel.

Safe treatments like minoxidil and spironolactone can help manage hair loss in breast cancer patients without increasing cancer risk.

Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.

Scalp cooling effectively reduces hair loss in breast cancer patients undergoing chemotherapy.

HER2-targeted or hormonal therapies improve quality of life for Sudanese breast cancer patients.

Oral dutasteride, minoxidil, and finasteride may help reduce hair loss in breast cancer survivors, but more research is needed.

Combining letrozole and quercetin in spanlastics may improve breast cancer treatment.

Topical minoxidil improves hair loss in 80% of women with breast cancer undergoing endocrine therapy.

PRP treatment may help improve hair density and thickness in breast cancer patients with therapy-induced hair loss.